-+ 0.00%
-+ 0.00%
-+ 0.00%

D. Boral Capital Maintains Buy on Trevi Therapeutics, Maintains $21 Price Target

Benzinga·03/19/2025 11:32:39
Listen to the news
D. Boral Capital analyst Jason Kolbert maintains Trevi Therapeutics (NASDAQ:TRVI) with a Buy and maintains $21 price target.